Therapy Areas: Hereditary Disorders
Concert Pharmaceuticals CEO to Depart Company in Early June 2017
5 June 2017 - - US-based biopharmaceutical company Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) chief financial officer, Ryan Daws, will be leaving the company in early June 2017 to return to investment banking, the company said.
He will be joining Baird as Managing director in the firm's Life Sciences and biotechnology Group.
Daws will continue to consult with the company, including through the closing of the pending asset purchase agreement with Vertex Pharmaceuticals, Inc.
Daws served as CFO of Concert since January 2014.
Concert has initiated a search to appoint a new CFO.
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform (deuterated chemical entity platform) to create novel medicines designed to address unmet patient needs.
The company's approach starts with approved drugs in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy.
Concert has a broad pipeline of innovative medicines targeting pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases and central nervous systems disorders.
Login
Username:

Password:


Related Headlines

Vertex Pharmaceuticals receives European Commission approval for ORKAMBI (lumacaftor/ivacaftor) To treat children with cystic fibrosis aged 1 to <2 years old

cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial

Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment with CFTR Modulators at the European Cystic Fibrosis Conference

First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant

Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Insmed completes adult patient enrolment in brensocatib pivotal ASPEN study

Vertex Receives FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes

Aluna Raises USD 15.3m in Series B Funding

First Patient Dosed in Adaptive Phage Therapeutics' PHAGE Clinical Trial Evaluating Phage Therapy in Cystic Fibrosis-related Respiratory Infection

CF Foundation Invests Up to USD 15m in ReCode Therapeutics for Development of mRNA Therapy

Markels Named to Arcturus Therapeutics Board of Directors

SpliSense commences first-in-human, Phase 1/2 clinical trial of SPL84 to treat cystic fibrosis

Sionna Therapeutics receives approval from US Food and Drug Administration for Investigational New Drug application of SION-638

Arcturus Forges Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines

Vanda Pharmaceuticals VPO-227 granted US FDA Orphan Drug Designation for the treatment of cholera